Herold Abellard
Psychiatry · Bronx, NYNPI 1497849350
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 361 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 24.7% of the total. 2025 is the largest year on record at $2,328, 3.6 times the $652 reported in 2019. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 361 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Vanda Pharmaceuticals Inc.$1K
- Lundbeck LLC$998
- Otsuka America Pharmaceutical, Inc.$945
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$629
- Neurocrine Biosciences, Inc.$323
- plus $2K from 22 others
What the payments were for
- Food & beverage$8,01599%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fanapt$375
- Lucemyra/Lofexidine$115
How this compares
$8,074 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 11 | $27,609 |
| VraylarCariprazine Hcl | 12 | $19,458 |
| AuvelityDextromethorphan Hbr/Bupropion | 16 | $13,589 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 29 | $5,209 |
| Lisdexamfetamine Dimesylate | 13 | $4,295 |
| Aripiprazole OdtAripiprazole | 13 | $3,484 |
| Duloxetine Hcl | 27 | $2,161 |
| Alprazolam | 175 | $1,900 |
| Zolpidem Tartrate ErZolpidem Tartrate | 32 | $1,523 |
| Clonazepam | 101 | $1,514 |
| Mirtazapine | 53 | $980 |
| Olanzapine | 22 | $912 |
| Naltrexone Hcl | 19 | $762 |
| Aripiprazole | 34 | $749 |
| Lorazepam | 93 | $563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $30 | $27,60911 claims |
| AbbVieVraylar | $1,991 | $19,45812 claims |
| Axsome Therapeutics, Inc.Auvelity | $183 | $13,58916 claims |
| Almatica Pharma LLCSertraline Hcl | $98 | $22034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Bronx
- George KruseBronx$1.2M
- Mahmood KazmiBronx$183K
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.